Exciting Postdoctoral Opportunity: Join our dynamic laboratory led by Tan Ince MD, PhD at Cornell University Ince, Tan (cornell.edu).
The position is funded through a new RO1 from NCI, extending until 2028.
Over the past 15 years, our lab has successfully established and distributed over 60 cell lines to researchers in 15+ countries. These cell lines have been deposited in public repositories such as ATCC, ECACC, and NCI Patient-Derived Models Repository (https://pdmr.cancer.gov/).
The ongoing study builds upon this foundation, aiming to develop defined reagents for selectively expanding matched normal, tumor, and stromal cells from the same solid tumor sample as reversible 2D/organoid cultures. Our goal is to deconstruct the cellular components of a tumor, expand them separately, and recombine them in a controlled experimental system. This innovative approach serves as both a disease model and a personalized oncology tool.
Simultaneously, we are advancing a liquid suspension culture method for various leukemia and lymphoma subtypes, with a manuscript currently in preparation.
Joining our lab offers the opportunity to learn cutting-edge cell culture fundamentals, skills, and methods. Successful candidates may contribute to establishing new tumor models that will be utilized and valued by researchers globally. For more information, please see the links below:
1) https://vivo.weill.cornell.edu/display/cwid-tai9015
2) https://www.linkedin.com/in/tan-ince-8892a6120/
3) Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours - PubMed (Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419. PMID: 26080861)
4) Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts - PubMed (Leukemia. 2013 Jun;27(6):1437-40. doi: 10.1038/leu.2012.337. PMID: 23246990)
5) Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes (Cancer Cell. 2007 Aug;12(2):160-70. doi: 10.1016/j.ccr.2007.06.013. PMID: 17692807)
6) https://www.usbio.net/search/media/?q=ince
7) https://www.scientia.global/wp-content/uploads/2016/12/Tan-Ince.pdf
Job Requirements
Candidates currently residing in the USA who have earned a Ph.D. or M.D./Ph.D. degree in cancer biology, molecular and cell biology, biochemistry, oncology, or a related field within the past few years are eligible to apply. Experience with mammalian cell culture is essential, and candidates should possess laboratory expertise in molecular and cellular biology techniques. A start date of May 2025 or earlier is preferred. To apply, please send a cover letter, CV, and three references, to tai9015@med.cornell.edu
Salary for this position ranges from $61,008 - $68,964. Weill Cornell Medicine provides the above salary range in compliance with the New York City law on Salary Transparency in Job Advertisements. The salary range listed is for full‐time employment not including benefits, bonuses, or clinical incentive compensation where applicable. The above salary range for New York City based roles represents WCM’s good faith and reasonable estimate of possible compensation at the time of posting. Weill Cornell Medicine is an Equal Employment Opportunity Employer and provides equal employment opportunities to all qualified applicants without regard to race, sex, sexual orientation, gender identity, national origin, color, age, religion, protected veteran or disability status, or genetic information.
Contact
- Pathology and Laboratory Medicine